Recurrence of differentiated thyroid cancer in the elderly

European Journal of Endocrinology

Volumn 168, Issue 4, 2013, Pages 549-556

  Hollenbeak, Christopher S ^a   Boltz, Melissa M ^a   Schaefer, Eric W ^a   Saunders, Brian D ^a   Goldenberg, David ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC IMAGING; DIFFERENTIATED THYROID CANCER; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROIDECTOMY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; REGISTRIES; THYROID NEOPLASMS;

EID: 84875191582     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0848     Document Type: Article

References (15)

1. Surveillance Epidemiology and End Results program 2010 US Mortality data 1969-2007. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released June 2010.
2. Coburn M, Teates D & Wanebo HJ. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131). Annals of Surgery 1994 219 587-593 (discussion 593-595). (doi:10.1097/00000658-199406000-00001)
3. Kloos R. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. Journal of Clinical Endocrinology and Metabolism 2010 95 1-8. (doi:10.1210/jc.2010-1500)
4. Surveillance Epidemiology and End Results program 2010 SEER Medicare research data 1986-2007. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released June 2010.
5. Sautter-Bihl ML, Raub J, Hetzel-Sesterheim M & Heinze HG. Differentiated thyroid cancer: prognostic factors and influence of treatment on the outcome in 441 patients. Strahlentherapie und Onkologie 2001 177 125-131. (doi:10.1007/PL00002392)
6. Leung AM, Dave S, Lee SL, Campion FX, Garber JR & Pearce EN. Actors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: a retrospective chart review. Thyroid Research 2011 4 9. (doi:10.1186/1756-6614- 4-9)
7. Mazzaferri EL & Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 1994 97 418-428. (doi:10.1016/0002-9343(94)90321-2)
8. DeGroot LJ, Kaplan EL, McCormickM& Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990 71 414-424. (doi:10.1210/jcem-71-2-414)
9. DeGroot LJ, Kaplan EL, Shukla MS, Salti G & Straus FH. Morbidity and mortality in follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 1995 80 2946-2953. (doi:10.1210/jc.80.10.2946)
10. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA & Fremgen A. Survival discriminants for differentiated thyroid cancer. American Journal of Surgery 1990 160 344-347. (doi:10.1016/S0002-9610(05)80539-2)
11. Miller BA, Scoppa SM & Feuer EJ. Racial/ethnic patterns in lifetime and age-conditional risk estimates for selected cancers. Cancer 2006 106 670-682. (doi:10.1002/cncr.21647)
12. Hollenbeak C, Wang L, Schneider P & Goldenberg D. Outcomes of thyroid cancer in African Americans. Ethnicity & Disease 2011 21 210-215.
13. Mitchell I, Livingston EH, Chang AY, Holt S, Snyder WH III, Lingvay I & Nwariaku FE. Trends in thyroid cancer demographics and surgical therapy in the United States. Surgery 2007 142 823-828 (discussion 828 e821). (doi:10.1016/j.surg.2007.09.011)
14. Yu GP, Li JC, Branovan D, McCormick S & Schantz SP. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 2010 20 465-473. (doi:10.1089/thy.2008.0281)
15. Mazzaferri EL. Treating differentiated thyroid carcinoma: where do we draw the line? Mayo Clinic Proceedings 1991 66 105-111. (doi:10.1016/S0025- 6196(12)61179-3)